To Get Help Now
Click Here
Today's Date:

J&J Reports “Agreement in Principle” Over Risperdal Marketing

AddThis Social Bookmark Button

In its quarterly regulatory filing, Johnson & Johnson said that it has achieved an “agreement in principle” with the U.S. Department of Justice in an attempt to settle the illegal marketing claims regarding the anti-psychotic drug Risperdal, the schizophrenia drug Invega, and a congestive heart failure treatment drug Natrecor.

The illegal marketing claims were brought by Massachusetts and California authorities, and while a settlement would resolve those claims, the company said in the filings that “issues remain open that must be resolved before the settlements can be finalized.” Al Wasilewski, a Johnson & Johnson spokesperson said, “We won’t speculate on when a settlement will be finalized.

According to previous reports by the Wall Street Journal and Bloomberg News, it is estimated that Johnson & Johnson will pay up to $2.2 billion to settle the investigations. disclaimer: This article: J&J Reports “Agreement in Principle” Over Risperdal Marketing was posted on Friday, August 3rd, 2012 at 8:12 pm at and is filed under Defective Drug Lawsuits.

« »

Comments are closed.